BioWorld

May 24, 2006

Pharmacopeia Rises On Deal With Cephalon: $15M Up Front

Shares of Pharmacopeia Drug Discovery Inc. jumped 26.3 percent after the company signed a drug discovery deal with Cephalon Inc. that includes a $15 million up-front fee and the potential for double-digit royalties. (BioWorld Today) Read More

Avanir Buys Alamo, Gains CNS Product, Sales Force

New River Starts Phase III Study For NRP104 Against Adult ADHD

BioWorld Releases First Report On Top 25 Biotechnology Drugs

Hold On Avastin Study Lifted After 60-Day Review By DSMB

Clinic Roundup

Other News To Note

Appointments And Advancements

Today's news in brief

BioWorld

BioWorld briefs for Dec. 31, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 31, 2025.

Illustration of magnifying glass looking at cancer in the brain

Researchers discover how glioblastoma tumors dodge chemotherapy

BioWorld MedTech

Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...

Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact

BioWorld

Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...

Big pharma taps fast Asia innovation in search of next Keytruda

BioWorld

Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...